Neumora Therapeutics, Inc. Common Stock
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. over the previous period. Total operating expenses were $187,526,000.
Profit Margin
| 2020 | 0 | -99.27M | |
|---|---|---|---|
| 2021 | 0 | -237.31M | |
| 2022 | 0 | -130.90M | |
| 2023 | 0 | -235.92M |
NMRA Income Statement (2020 – 2023)
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
Revenue | ||||
Revenue | 0 | 0 | 0 | 0 |
Cost of revenue | 668K | 0 | 0 | 0 |
Gross profit | -668K | 0 | 0 | 0 |
Operating exp. | ||||
Research and development | 142.71M | 104.74M | 212.77M | 87.12M |
Selling and marketing | -668K | 0 | 0 | 0 |
Total operating expenses | 187.52M | 135.87M | 237.32M | 95.51M |
Operating income | -188.19M | -135.87M | -237.32M | -95.51M |
Other income (expenses), net | -47.46M | 405K | 11K | -3.75M |
Income before tax | -235.65M | -130.90M | -237.31M | -99.27M |
Income tax expense | 268K | -4.56M | 0 | -101.29K |
Net income | -235.92M | -130.90M | -237.31M | -99.27M |
Earnings per share | ||||
Basic EPS | -1.49 | -0.86 | -1.56 | -0.65 |
Diluted EPS | -1.49 | -0.86 | -1.56 | -0.65 |
| Data source |